Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses.
+ 2 more risks
Limited growth with imperfect balance sheet.
Share Price & News
How has Visioneering Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VTI's share price has been volatile over the past 3 months.
7 Day Return
AU Medical Equipment
1 Year Return
AU Medical Equipment
Return vs Industry: VTI underperformed the Australian Medical Equipment industry which returned -1.7% over the past year.
Return vs Market: VTI underperformed the Australian Market which returned -22.8% over the past year.
Price Volatility Vs. Market
How volatile is Visioneering Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDid Visioneering Technologies, Inc. (ASX:VTI) Insiders Buy Up More Shares?
3 months ago | Simply Wall StSuch Is Life: How Visioneering Technologies (ASX:VTI) Shareholders Saw Their Shares Drop 59%
4 months ago | Simply Wall StWe're A Little Worried About Visioneering Technologies's (ASX:VTI) Cash Burn Rate
Is Visioneering Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VTI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate VTI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: VTI is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: VTI is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VTI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VTI is overvalued based on its PB Ratio (4x) compared to the AU Medical Equipment industry average (3.2x).
How is Visioneering Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if VTI's forecast earnings growth is above the savings rate (1.1%).
Earnings vs Market: Insufficient data to determine if VTI's earnings are forecast to grow faster than the Australian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: VTI's revenue (35.7% per year) is forecast to grow faster than the Australian market (4.2% per year).
High Growth Revenue: VTI's revenue (35.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VTI's Return on Equity is forecast to be high in 3 years time
How has Visioneering Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VTI is currently unprofitable.
Growing Profit Margin: VTI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VTI is unprofitable, and losses have increased over the past 5 years at a rate of -18.4% per year.
Accelerating Growth: Unable to compare VTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VTI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.7%).
Return on Equity
High ROE: VTI has a negative Return on Equity (-1284.83%), as it is currently unprofitable.
How is Visioneering Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: VTI's short term assets ($5.2M) exceed its short term liabilities ($1.8M).
Long Term Liabilities: VTI's short term assets ($5.2M) exceed its long term liabilities ($3.1M).
Debt to Equity History and Analysis
Debt Level: VTI's debt to equity ratio (291.5%) is considered high.
Reducing Debt: Insufficient data to determine if VTI's debt to equity ratio has reduced over the past 5 years.
Inventory Level: VTI has a high level of physical assets or inventory.
Debt Coverage by Assets: VTI's debt is covered by short term assets (assets are 1.8x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VTI has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: VTI has less than a year of cash runway if free cash flow continues to reduce at historical rates of -24.8% each year
What is Visioneering Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate VTI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VTI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VTI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VTI's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stephen Snowdy (49yo)
Dr. Stephen Snowdy, Ph.D., has been Chief Executive Officer of Visioneering Technologies, Inc. June 2013, its Executive Director since November 25, 2008 and served as its President. Dr. Snowdy is a Princip ...
|CEO & Executive Director||6.75yrs||no data||no data|
|Founder & Medical Adviser||no data||no data||no data|
|Chief Financial Officer||1.25yrs||no data||no data|
|Senior Vice President of Sales & Marketing||3.5yrs||no data||no data|
|Company Secretary||1.08yrs||no data||no data|
|Executive Director of Marketing||no data||no data||no data|
|Executive Director of Professional Affairs||2.5yrs||no data||no data|
Experienced Management: VTI's management team is considered experienced (2.5 years average tenure).
|CEO & Executive Director||6.75yrs||no data||no data|
|Independent Non-Executive Director||11.33yrs||no data||0.091% $6.8k|
|Non-Executive Chairman of the Board||no data||no data||no data|
|Independent Non-Executive Director||3.08yrs||no data||0.023% $1.7k|
|Independent Non-Executive Director||2.25yrs||no data||no data|
|Independent Non-Executive Director||2.83yrs||no data||no data|
Experienced Board: VTI's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 50.2%.
Visioneering Technologies, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Visioneering Technologies, Inc.
- Ticker: VTI
- Exchange: ASX
- Founded: 2008
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: AU$7.453m
- Shares outstanding: 465.80m
- Website: https://www.vtivision.com
Number of Employees
- Visioneering Technologies, Inc.
- 10745 Westside Way
- Suite 200
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VTI||ASX (Australian Securities Exchange)||Class A Common Stock||AU||AUD||No data|
|VTI||ASX (Australian Securities Exchange)||Yes||CDI 1:1||AU||AUD||Mar 2017|
|VTI||CHIA (Chi-X Australia)||Yes||CDI 1:1||AU||AUD||Mar 2017|
Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses. The company offers NaturalVue, a contact lense for adults with presbyopia and children with myopia. It operates in the United States, Australia, New Zealand, Europe, Hong Kong, and Singapore. The company was founded in 2008 and is headquartered in Alpharetta, Georgia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/28 10:52|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.